Clinical trial · Interventional
Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer
Phase 3 Study to Evaluate the Role of Total Neoadjuvant Chemotherapy in Partial Responders of Locally Advanced Ovarian Cancer Cancers (NeoPAR Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
neoadjuvant chemotherapy in stage III and IV ovarian cancer is given in 3-4 cycles with patients who R0 surgical resection is less likely to occur, in this study will assess total neoadjuvant chemotherapy 6 cycles then interval debulking surgery (experimental arm) versus 4 cycles then interval debulking surgery (control arm) in patients who achieve partial response or stationary disease by imaging after 3- 4 cycles of neoadjuvant chemotherapy, investigators'' primary end points will be event free survival, safety and tolerability and time to relapse, our secondary end points will be overall survival and surgical morbidity and mortality
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage III and IV Ovarian Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neoadjuvant chemotherapy (Paclitaxel and Carboplatin) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- total neoadjuvant 6 cycles of chemotherapy
- description
- patients who have stationary disease or partial response by MRI after 3 cycles, investigators will give another 3 cycles of chemotherapy to complete six cycles
- interventionNames
- Drug: Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)
Primary outcomes (1)
- measure
- event free survival
- timeFrame
- it will be measured after 24 months, 36 months and 50 months from neoadjuvant chemotherapy and surgery
- description
- the length of time after primary treatment for a cancer ends that the patient remains free of certain complications or events that the treatment was intended to prevent or delay. it will be measured after 24 months, 36 months and 50 months from neoadjuvant chemotherapy and surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. \> 18 years of age 2. Recently diagnosed with stage III and IV OC 3. Patients eligible for Platinum-based CTH 4. Patients have PR or SD after 3-4 cycles of NACT Exclusion Criteria: 1. Relapsed ovarian cancer 2. patients ineligible for Platinum-based CTH 3. Patient not candidate for IDS 4. stage I, II OC 5. Patients progressed after 3 cycles 7-Patients do not tolerate CTH
References
Publications (0)
Data not yet available